Primus In News
Tarnished by cough syrup deaths, India’s pharma industry tries to look beyond the stupor
21-07-2023
Nilaya Varma, Co-Founder and CEO of Primus Partners shares his views on the impact of the COVID-19 pandemic and the Russia-Ukraine war on vaccine exports from India, especially to African and Commonwealth of Independent States (CIS) countries. In addition, he stresses that the increasing cost of raw materials and the withdrawal of GST exemption has exacerbated challenges for Indian pharma companies. Read Now!
Explore Related Insights
- India missed Intel twice. Can it afford to fumble Tesla’s chip play?
- Success & Gender Equity: Exclusive Interview with Aarti Harbhajanka, Consultant turned Entrepreneur
- UPI Circle for delegate payments launched: Multiple people can use one UPI account; how to use UPI Circle, transaction limit
- Balancing Scales: How Traffic Risk, Revenue Guarantees Shape Infra Landscape